1. Generics Bulletin
  2. >>Business

Hyloris And Purna Strike Value-Added Development Deal

Miconazole And Domiphen Bromide Combination Will Treat Vulvovaginal Candidiasis

 
• By Dave Wallace

Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.

Value Added Dictionary Definition Highlighter
Hyloris and Purna Female Healthcare strike a value-added medicines deal • Source: Shutterstock

Belgian value-added medicines specialist Hyloris Pharmaceuticals has struck a deal worth up to €4.3m ($5.2m) with Purna Female Healthcare to develop an innovative “dual mode-of-action” treatment for severe and recurrent vulvovaginal candidiasis that combines miconazole and domiphen bromide.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.